PURPOSE OF REVIEW: The novel severe respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has caused a world-wide pandemic with devastating effects . Fortunately, most children display only mild-to-moderate symptoms, but there are a subset that will have severe symptoms warranting treatment . This review evaluates the current evidence for antiviral and anti-inflammatory treatment of acute SARS-COV-2 infections, including coronavirus disease 2019 in pediatrics .

RECENT FINDINGS: Treatment recommendations continue to evolve with emerging results from clinical trials . Initial therapies were tailored to repurposed medications, and have now transitioned toward more specific antiviral therapy . In addition to specific antiviral therapy, there is also support to modulate the immune system and reduce inflammatory damage seen in coronavirus disease 2019 . Much of the data result from adult studies with subsequent extrapolation to pediatrics .

SUMMARY: Recommended therapy will continue to adapt as results return from clinical trials . A continued commitment from the National Institutes of Health and research community to assist in determining optimal therapies for pediatric patients is essential . Until then, most recommendations will likely be informed from the results seen in adult populations.